• Argenica Therapeutics (AGN) doses the first subject in its phase one clinical trial of ARG-007 in healthy volunteers
• The trial looks to assess the safety and tolerability of the treatment across four cohorts of healthy adult volunteers
• The first subject showed no serious safety issues 24 hours after dosing, which has encouraged the company to continue treating the remaining participants over the next three days
• Following the dosing, all follow-up data will be presented to the Scientific Review Committee, who will then confirm the progress of the trial in the next cohort
• Argenica Therapeutics last traded at 45 cents at 3:25 pm AEDT

Argenica Therapeutics (AGN) has dosed the first subject in its phase one clinical trial of ARG-007 in healthy volunteers.

The trial is being conducted at Linear Clinical Research facility in Perth and is assessing the safety and tolerability of ARG-007 across four cohorts of health adult volunteers, with each cohort receiving an ascending dose.

The aim of the treatment is to protect brain tissue against damage during a stroke, with further potential to enhance recovery once a stroke has taken place.

The first dosed subject – a healthy volunteer – showed no serious safety issues 24 hours after dosing. As such, dosing of the remaining participants in the first cohort will be completed over the next three days.

Following the dosing, all follow-up data will be presented to the Scientific Review Committee, who will then confirm the progress of the trial in the next cohort.

Argenica Therapeutics last traded at 45 cents at 3:25 pm AEDT.